Skip to content
Gallery
Diosa Ara Research Database (Confidential)
Research Dashboard
Share
Explore
Literature

The immunobiology of preterm labor and birth: intra-amniotic inflammation or breakdown of maternal–fetal homeostasis

Nardhy Gomez-Lopez; Jose Galaz; Derek Miller; Marcelo Farias-Jofre; Zhenjie Liu; Marcia Arenas-Hernandez; Valeria Garcia-Flores; Zachary Shaffer; Jonathan M Greenberg; Kevin R Theis; Roberto Romero
2022

Abstract

In brief The syndrome of preterm labor comprises multiple established and novel etiologies. This review summarizes the distinct immune mechanisms implicated in preterm labor and birth and highlights potential strategies for its prevention. Abstract Preterm birth, the leading cause of neonatal morbidity and mortality worldwide, results from preterm labor, a syndrome that includes multiple etiologies. In this review, we have summarized the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth, as well as novel etiologies non-associated with intra-amniotic inflammation (i.e. formally known as idiopathic). While the intra-amniotic inflammatory responses driven by microbes (infection) or alarmins (sterile) have some overlap in the participating cellular and molecular processes, the distinct natures of these two conditions necessitate the implementation of specific approaches to prevent adverse pregnancy and neonatal outcomes. Intra-amniotic infection can be treated with the correct antibiotics, whereas sterile intra-amniotic inflammation could potentially be treated by administering a combination of anti-inflammatory drugs (e.g. betamethasone, inflammasome inhibitors, etc.). Recent evidence also supports the role of fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases diagnosed as idiopathic. Moreover, herein we also provide evidence of two maternally-driven immune mechanisms responsible for preterm births formerly considered to be idiopathic. First, the impairment of maternal Tregs can lead to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses. Secondly, homeostatic macrophages were shown to be essential for maintaining pregnancy and promoting fetal development, and the adoptive transfer of homeostatic M2-polarized macrophages shows great promise for preventing inflammation-induced preterm birth. Collectively, in this review, we discuss the established and novel immune mechanisms responsible for preterm birth and highlight the potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor leading to preterm birth.

Key points

● Preterm birth, the leading cause of neonatal morbidity and mortality worldwide, results from preterm labor, a syndrome that includes multiple etiologies
● The impairment of maternal Tregs can lead to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses
● Intra-amniotic infection can be treated using the right antibiotics, whereas sterile intra-amniotic inflammation could be potentially treated using a combination of anti-inflammatory drugs
● We have shown that the impairment of maternal Tregs leads to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses (Fig. 2A)
● We have demonstrated the importance of homeostatic macrophages for maintaining pregnancy and promoting fetal development as well as the effectiveness of the adoptive transfer of M2-polarized macrophages for preventing inflammation-induced preterm birth (Fig. 2B)
● In this review, we have discussed established and novel immune mechanisms responsible for preterm birth and highlighted potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor

Summary

Conclusion Here the authors have provided an overview of the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth.
The authors have described the current evidence supporting fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases (Fig. 1C).
These findings represent an exciting area of future research focused on further elucidating the fetal immune mechanisms implicated in such a response.
The authors provided evidence of two potential immune mechanisms responsible for a subset of preterm births formerly considered to be idiopathic.
The authors have demonstrated the importance of homeostatic macrophages for maintaining pregnancy and promoting fetal development as well as the effectiveness of the adoptive transfer of M2-polarized macrophages for preventing inflammation-induced preterm birth (Fig. 2B).
In this review, the authors have discussed established and novel immune mechanisms responsible for preterm birth and highlighted potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor
KEY POINTS Intra-amniotic inflammation, driven by microbes ascending from the lower genital tract or by alarmins released upon cellular stress or damage, is the best-established causal link to preterm labor and birth.
A breakdown of such maternal-fetal tolerance, either through the aberrant activation of effector T cells or the impaired functionality of Tregs, can result in preterm labor and birth.
Macrophages represent a critical cellular component of the maternal-fetal interface.
Such cells exert anti-inflammatory functions to promote maternal-fetal homeostasis until term, when they acquire a pro-inflammatory phenotype to promote labor.
The importance of macrophages was further established by showing that the impairment of these cells during pregnancy results in preterm labor and birth.
Homeostatic macrophages may represent a viable cellular approach to treat sterile intra-amniotic inflammation
Declaration of interest The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Equils O, Kellogg C, Mcgregor J, Gravett M, Neal-Perry G Gabay C 2020.
The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complicationsdagger.
The recruitment and activation of leukocytes into the immune cervix: further support that cervical remodeling involves an immune and inflammatory mechanism.
Timing of neutrophil activation and expression of proinflammatory markers do not support a role for neutrophils in cervical ripening in the mouse.

Introduction

Preterm birth, the leading cause of neonatal morbidity and mortality worldwide, results from preterm labor, a syndrome that includes multiple etiologies. In this review, we have summarized the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth. While the intra-amniotic inflammatory responses driven by microbes (infection) or alarmins (sterile) have some overlap in the participating cellular and molecular processes, the distinct natures of these two conditions necessitate the implementation of specific approaches to prevent adverse pregnancy and neonatal outcomes. Intra-amniotic infection can be treated using the correct antibiotics, whereas sterile intra-amniotic inflammation could potentially be treated using a combination of anti-inflammatory drugs (e.g., betamethasone, inflammasome inhibitors, etc.). Recent evidence also supports a role for fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases. Moreover, here we also provide evidence of two potential immune mechanisms responsible for a subset of preterm births formerly considered to be idiopathic. First, the impairment of maternal Tregs can lead to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses. Second, homeostatic macrophages were shown to be essential for maintaining pregnancy and promoting fetal development, and the adoptive transfer of homeostatic M2-polarized macrophages shows great promise for preventing inflammation-induced preterm birth. Collectively, in this review, we discuss established and novel immune mechanisms responsible for preterm birth and highlight potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor.
In brief: The syndrome of preterm labor comprises multiple established and novel etiologies. This review summarizes the distinct immune mechanisms implicated in preterm labor and birth and highlights potential strategies for its prevention.
In this review, we first discuss the discovery, clinical definitions, and immune mechanisms implicated in intra-amniotic infection and sterile intra-amniotic inflammation. Moreover, we discuss the current and potential approaches that can be used to treat these two distinct clinical conditions. Next, we discuss the activation of the fetal immune system as a novel mechanism leading to preterm birth. We then focus on the mechanisms whereby maternal effector T cells, Tregs, and macrophages participate in successful pregnancy. In addition, we review the evidence implicating each subset in the pathophysiology of preterm labor and birth, and potential therapeutic approaches that can be used to target these cells. We aim to provide an overview of key immunological processes implicated in preterm labor and birth, which can provide deeper understanding, highlight gaps in knowledge, and provide potential targets for future therapies that can be used to treat this devastating obstetrical syndrome.
Representative diagrams of the fetus and amniotic cavity showing the causative agents and responding immune cells associated with distinct immune responses leading to preterm labor. (A) Intra-amniotic infection is typically triggered by the ascending invasion of bacteria from lower genital tract and is characterized by a massive local immune response including elevated concentrations of inflammatory mediators such as interleukin (IL)-6 and abundant neutrophils, monocytes/macrophages, and T cells. (B) Sterile intra-amniotic inflammation can be triggered by endogenous alarmins and involves elevated concentrations of inflammatory mediators such as IL-6 and a mild infiltration of immune cells such as neutrophils, monocytes/macrophages, and T cells. (C) A subset of cases of preterm labor and birth, formerly considered to be idiopathic, can be driven by the fetal immune system, as indicated by the activation and increased presence of fetal T cells and their mediators in the amniotic cavity. This immune response may also include the activation of amniotic fluid resident innate immune cells such as neutrophils and monocytes/macrophages.
Considering the above demonstrations showing a strong relationship between intra-amniotic infection and spontaneous preterm birth as well as its adverse consequences, numerous randomized clinical trials have attempted to manage such risks using antibiotic therapy. Multiple clinical trials in patients with PPROM indicated that antibiotic therapy is associated with a longer latency period (time between the onset of PPROM and delivery) as well as reduced rates of clinical chorioamnionitis and neonatal sepsis (Mercer and Arheart, 1995, Kenyon et al, 2001a, Kenyon et al, 2013). Thus, antibiotics are considered a standard of care for women with PPROM (Ehrenberg and Mercer, 2001, Yudin et al, 2009, Thomson et al, 2019, American College of Obstetricians and Gynecologists, 2020). However, most studies evaluating the potential usefulness of antibiotics to prolong gestational length and reduce neonatal morbidity in women with preterm labor and intact membranes have been unsuccessful (Newton et al, 1989, Romero et al, 1993a, Gordon et al, 1995, Kenyon et al, 2001b). Such disparity in the success of antibiotic treatment could be explained by the greater prevalence of intra-amniotic infection in women with PPROM compared to those with preterm labor and intact membranes (Goncalves et al, 2002), and thus the benefits of antibiotics lies in their inherent function of killing bacteria or inhibiting bacterial growth. Therefore, it is imperative to evaluate the microbial and inflammatory status of the amniotic fluid to select the subset of women with preterm labor and intact membranes who will benefit from antibiotic treatment. Indeed, recent investigations have demonstrated that the utilization of an appropriate antibiotic regimen can improve adverse perinatal outcomes in women with preterm labor and intact membranes (Yoon et al, 2019), PPROM (Lee et al, 2016a, Lee et al, 2016b), or cervical insufficiency (Oh et al, 2019b, Yeo et al, 2021) who were diagnosed with intra-amniotic infection/inflammation. This antibiotic regimen includes clarithromycin, ceftriaxone and metronidazole, based on their pharmacokinetics (Kafetzis et al, 1983, Visser and Hundt, 1984, Amon, 1985, Matsuda et al, 1988, Witt et al, 2003, Park et al, 2012) and broad coverage for bacteria that are typically found in the amniotic fluid (Romero et al, 1989c, Yoon et al, 1998, DiGiulio et al, 2010, Mendz et al, 2013, Romero et al, 2014b, Romero et al, 2014c, Romero et al, 2015b, Romero et al, 2015d, Romero et al, 2015c). Specifically, the use of clarithromycin is strongly supported by its coverage of genital mycoplasmas as well as more efficient trans-placental passage than other macrolides (Witt et al, 2003, Park et al, 2012). Such protective effects of clarithromycin were recently demonstrated by the reduced rates of preterm birth and neonatal mortality observed in mice treated with this antibiotic after the intra-amniotic injection of Ureaplasma parvum (Motomura et al, 2020b). Furthermore, ceftriaxone and metronidazole offer excellent antimicrobial coverage for aerobic and anaerobic bacteria, respectively (Klein and Cunha, 1995, Freeman et al, 1997, Lamb et al, 2002, Brook et al, 2013), and can also cross the placenta efficiently (Kafetzis et al, 1983, Visser and Hundt, 1984, Amon, 1985, Matsuda et al, 1988). Therefore, this recent evidence supports the use of amniocentesis to evaluate the infectious status of the amniotic fluid and the treatment of intra-amniotic infection with the optimal antibiotic therapy.
We aim to provide an overview of key immunological processes implicated in preterm labor and birth, which can provide deeper understanding, highlight gaps in knowledge, and provide potential targets for future therapies that can be used to treat this devastating obstetrical syndrome

Conclusion

In summary, here we have provided an overview of the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth. While the inflammatory processes driven by microbes (infection) or alarmins (sterile) have some overlap in their participating cellular and molecular processes, the distinct natures of these two conditions necessitate the implementation of specific approaches to prevent adverse pregnancy and neonatal outcomes (Fig. 1A&B). Intra-amniotic infection can be treated using the right antibiotics, whereas sterile intra-amniotic inflammation could be potentially treated using a combination of anti-inflammatory drugs (e.g., betamethasone, inflammasome inhibitors, etc.). Importantly, we have also described the current evidence supporting fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases (Fig. 1C). These findings represent an exciting area of future research focused on further elucidating the fetal immune mechanisms implicated in such a response. Recently, we also provided evidence of two potential immune mechanisms responsible for a subset of preterm births formerly considered to be idiopathic. In the first, we have shown that the impairment of maternal Tregs leads to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses (Fig. 2A). Second, we have demonstrated the importance of homeostatic macrophages for maintaining pregnancy and promoting fetal development as well as the effectiveness of the adoptive transfer of M2-polarized macrophages for preventing inflammation-induced preterm birth (Fig. 2B). Collectively, in this review, we have discussed established and novel immune mechanisms responsible for preterm birth and highlighted potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor.
In summary, here we have provided an overview of the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth. While the inflammatory processes driven by microbes (infection) or alarmins (sterile) have some overlap in their participating cellular and molecular processes, the distinct natures of these two conditions necessitate the implementation of specific approaches to prevent adverse pregnancy and neonatal outcomes (Fig. 1A&B). Intra-amniotic infection can be treated using the right antibiotics, whereas sterile intra-amniotic inflammation could be potentially treated using a combination of anti-inflammatory drugs (e.g., betamethasone, inflammasome inhibitors, etc.). Importantly, we have also described the current evidence supporting fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases (Fig. 1C). These findings represent an exciting area of future research focused on further elucidating the fetal immune mechanisms implicated in such a response. Recently, we also provided evidence of two potential immune mechanisms responsible for a subset of preterm births formerly considered to be idiopathic. In the first, we have shown that the impairment of maternal Tregs leads to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses (Fig. 2A). Second, we have demonstrated the importance of homeostatic macrophages for maintaining pregnancy and promoting fetal development as well as the effectiveness of the adoptive transfer of M2-polarized macrophages for preventing inflammation-induced preterm birth (Fig. 2B). Collectively, in this review, we have discussed established and novel immune mechanisms responsible for preterm birth and highlighted potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor.

Funding

This research was supported by the Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S Department of Health and Human Services (NICHD/NIH/DHHS) under Contract No HHSN275201300006C. This research was also supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health. R.R. has contributed to this work as part of his official duties as an employee of the United States Federal Government. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Footnotes

Full text

Front matter
Other Formats
Actions
Name your collection: /]*" title="The following characters are not allowed in the Name field: "&=/" maxlength="" data-ga-category="collections_button" data-ga-action="create_collection" data-ga-label="non_favorties_collection">
Name must be less than characters
Choose a collection: Unable to load your collection due to an error Please try again
Share
Permalink
RESOURCES
Journal List
HHS Author Manuscripts
PMC9233101
Reproduction. Author manuscript; available in PMC 2022 Jun 25.
Published in final edited form as: Reproduction. 2022 Jun 20; 164(2): R11–R45.
Published online 2022 Jun 20. doi: 10.1530/REP-22-0046
PMCID: PMC9233101
NIHMSID: NIHMS1813022
PMID: 35559791
The Immunobiology of Preterm Labor and Birth: Intra-Amniotic Inflammation or Breakdown of Maternal-Fetal Homeostasis
N.G.-L. conceptualized the manuscript and supervised the study. N.G.-L., J.G., D.M., M.F.-J., Z.L., M.A.-H., V.G.-F., Z.S., J.G., K.R.T., and R.R. drafted and revised the manuscript, performed literature review, created figures, and/or provided intellectual input. All authors approved the final version of the manuscript.
The publisher's final edited version of this article is available at Reproduction
Abstract
Preterm birth, the leading cause of neonatal morbidity and mortality worldwide, results from preterm labor, a syndrome that includes multiple etiologies. In this review, we have summarized the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth. While the intra-amniotic inflammatory responses driven by microbes (infection) or alarmins (sterile) have some overlap in the participating cellular and molecular processes, the distinct natures of these two conditions necessitate the implementation of specific approaches to prevent adverse pregnancy and neonatal outcomes. Intra-amniotic infection can be treated using the correct antibiotics, whereas sterile intra-amniotic inflammation could potentially be treated using a combination of anti-inflammatory drugs (e.g., betamethasone, inflammasome inhibitors, etc.). Recent evidence also supports a role for fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases. Moreover, here we also provide evidence of two potential immune mechanisms responsible for a subset of preterm births formerly considered to be idiopathic. First, the impairment of maternal Tregs can lead to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses. Second, homeostatic macrophages were shown to be essential for maintaining pregnancy and promoting fetal development, and the adoptive transfer of homeostatic M2-polarized macrophages shows great promise for preventing inflammation-induced preterm birth. Collectively, in this review, we discuss established and novel immune mechanisms responsible for preterm birth and highlight potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor.
In brief: The syndrome of preterm labor comprises multiple established and novel etiologies. This review summarizes the distinct immune mechanisms implicated in preterm labor and birth and highlights potential strategies for its prevention.
In this review, we first discuss the discovery, clinical definitions, and immune mechanisms implicated in intra-amniotic infection and sterile intra-amniotic inflammation. Moreover, we discuss the current and potential approaches that can be used to treat these two distinct clinical conditions. Next, we discuss the activation of the fetal immune system as a novel mechanism leading to preterm birth. We then focus on the mechanisms whereby maternal effector T cells, Tregs, and macrophages participate in successful pregnancy. In addition, we review the evidence implicating each subset in the pathophysiology of preterm labor and birth, and potential therapeutic approaches that can be used to target these cells. We aim to provide an overview of key immunological processes implicated in preterm labor and birth, which can provide deeper understanding, highlight gaps in knowledge, and provide potential targets for future therapies that can be used to treat this devastating obstetrical syndrome.
Intra-amniotic infection: the most well-known etiology of preterm labor and birth
Distinct immune responses in the amniotic cavity of women with preterm labor.
Representative diagrams of the fetus and amniotic cavity showing the causative agents and responding immune cells associated with distinct immune responses leading to preterm labor. (A) Intra-amniotic infection is typically triggered by the ascending invasion of bacteria from lower genital tract and is characterized by a massive local immune response including elevated concentrations of inflammatory mediators such as interleukin (IL)-6 and abundant neutrophils, monocytes/macrophages, and T cells. (B) Sterile intra-amniotic inflammation can be triggered by endogenous alarmins and involves elevated concentrations of inflammatory mediators such as IL-6 and a mild infiltration of immune cells such as neutrophils, monocytes/macrophages, and T cells. (C) A subset of cases of preterm labor and birth, formerly considered to be idiopathic, can be driven by the fetal immune system, as indicated by the activation and increased presence of fetal T cells and their mediators in the amniotic cavity. This immune response may also include the activation of amniotic fluid resident innate immune cells such as neutrophils and monocytes/macrophages.
Considering the above demonstrations showing a strong relationship between intra-amniotic infection and spontaneous preterm birth as well as its adverse consequences, numerous randomized clinical trials have attempted to manage such risks using antibiotic therapy. Multiple clinical trials in patients with PPROM indicated that antibiotic therapy is associated with a longer latency period (time between the onset of PPROM and delivery) as well as reduced rates of clinical chorioamnionitis and neonatal sepsis (Mercer and Arheart, 1995, Kenyon et al, 2001a, Kenyon et al, 2013). Thus, antibiotics are considered a standard of care for women with PPROM (Ehrenberg and Mercer, 2001, Yudin et al, 2009, Thomson et al, 2019, American College of Obstetricians and Gynecologists, 2020). However, most studies evaluating the potential usefulness of antibiotics to prolong gestational length and reduce neonatal morbidity in women with preterm labor and intact membranes have been unsuccessful (Newton et al, 1989, Romero et al, 1993a, Gordon et al, 1995, Kenyon et al, 2001b). Such disparity in the success of antibiotic treatment could be explained by the greater prevalence of intra-amniotic infection in women with PPROM compared to those with preterm labor and intact membranes (Goncalves et al, 2002), and thus the benefits of antibiotics lies in their inherent function of killing bacteria or inhibiting bacterial growth. Therefore, it is imperative to evaluate the microbial and inflammatory status of the amniotic fluid to select the subset of women with preterm labor and intact membranes who will benefit from antibiotic treatment. Indeed, recent investigations have demonstrated that the utilization of an appropriate antibiotic regimen can improve adverse perinatal outcomes in women with preterm labor and intact membranes (Yoon et al, 2019), PPROM (Lee et al, 2016a, Lee et al, 2016b), or cervical insufficiency (Oh et al, 2019b, Yeo et al, 2021) who were diagnosed with intra-amniotic infection/inflammation. This antibiotic regimen includes clarithromycin, ceftriaxone and metronidazole, based on their pharmacokinetics (Kafetzis et al, 1983, Visser and Hundt, 1984, Amon, 1985, Matsuda et al, 1988, Witt et al, 2003, Park et al, 2012) and broad coverage for bacteria that are typically found in the amniotic fluid (Romero et al, 1989c, Yoon et al, 1998, DiGiulio et al, 2010, Mendz et al, 2013, Romero et al, 2014b, Romero et al, 2014c, Romero et al, 2015b, Romero et al, 2015d, Romero et al, 2015c). Specifically, the use of clarithromycin is strongly supported by its coverage of genital mycoplasmas as well as more efficient trans-placental passage than other macrolides (Witt et al, 2003, Park et al, 2012). Such protective effects of clarithromycin were recently demonstrated by the reduced rates of preterm birth and neonatal mortality observed in mice treated with this antibiotic after the intra-amniotic injection of Ureaplasma parvum (Motomura et al, 2020b). Furthermore, ceftriaxone and metronidazole offer excellent antimicrobial coverage for aerobic and anaerobic bacteria, respectively (Klein and Cunha, 1995, Freeman et al, 1997, Lamb et al, 2002, Brook et al, 2013), and can also cross the placenta efficiently (Kafetzis et al, 1983, Visser and Hundt, 1984, Amon, 1985, Matsuda et al, 1988). Therefore, this recent evidence supports the use of amniocentesis to evaluate the infectious status of the amniotic fluid and the treatment of intra-amniotic infection with the optimal antibiotic therapy.
Sterile intra-amniotic inflammation: the new kid on the block among the etiologies of preterm labor and birth
As an initial effort to distinguish the inflammatory processes taking place in sterile intra-amniotic inflammation from those observed in intra-amniotic infection, our group performed a network analysis of the cytokines and other known inflammatory mediators in the amniotic fluid of women who underwent preterm labor with intact membranes and were diagnosed with either sterile intra-amniotic inflammation or intra-amniotic infection (Romero et al, 2015a). This network analysis revealed the enrichment of IL-1α and high mobility group box 1 (HMGB1) in the amniotic fluid of women with sterile intra-amniotic inflammation (Romero et al, 2015a). Multiple studies have demonstrated the importance of IL-1α in the physiologic and pathologic processes of parturition (Romero et al, 1989a, Romero et al, 1990a, Nadeau-Vallee et al, 2016a, Nadeau-Vallee et al, 2016b, Nadeau-Vallee et al, 2017b, Equils et al, 2020), as evidenced by its increased concentrations in the amniotic fluid of women with intra-amniotic inflammation (Romero et al, 1992b) as well as mechanistic demonstrations that the systemic administration of IL-1 induced preterm parturition in mice (Romero et al, 1991a), which could be prevented by pre-treatment with the IL-1 receptor antagonist (IL-1RA) (Romero and Tartakovsky, 1992). Clinical investigations have also shown that women with sterile intra-amniotic inflammation who had higher amniotic fluid concentrations of HMGB1 delivered sooner than women with lower concentrations, implicating this mediator in the pathological process of preterm labor and birth (Romero et al, 2014c). Notably, both IL-1α and HMGB1 are known damage-associated molecular patterns (DAMPs) or alarmins (Oppenheim and Yang, 2005, Lotze et al, 2007, Bianchi, 2007, Rider et al, 2017), and thus our network analysis hinted at a key role for alarmins in the pathophysiology of sterile intra-amniotic inflammation.
In search of the putative mechanisms whereby alarmins in the amniotic cavity can induce preterm labor and birth, we first turned to the human chorioamniotic membranes. The chorioamniotic membranes are the tissues surrounding the amniotic cavity containing the fetus (Bourne, 1962), and their activation is a component of the common pathway of labor (Norwitz et al, 1999, Romero et al, 2006b, Smith, 2007, Romero et al, 2014c). Given that the chorioamniotic membranes are in direct contact with the amniotic fluid, in vitro studies were undertaken to evaluate the pathways that were affected upon exposure of these tissues to HMGB1 (Bredeson et al, 2014, Plazyo et al, 2016, Menon et al, 2016). We showed that HMGB1 induced a pro-inflammatory response in the chorioamniotic membranes by increasing the secretion of IL-6 and mature IL-1β as well as by upregulating the expression of pro-inflammatory transcripts such as NFKB1, ILIB, IL6, TNF, IL1A, and IFNG and the HMGB1 receptors RAGE and TLR2 (Plazyo et al, 2016). Notably, HMGB1 exposure also upregulated the mRNA and protein expression of the inflammasome components nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family pyrin domain-containing 3 protein (NLRP3), NOD 1 and 2, and absent in melanoma 2 (AIM2) in the chorioamniotic membranes (Plazyo et al, 2016). Similarly, we have demonstrated the release of IL-6 and IL-8, the upregulated mRNA expression of NFKB1, ILIB, IL6, RAGE, TLR2, NOD, and the increased protein expression of NLRP3 in the chorioamniotic membranes exposed to S100A12 (Motomura et al, 2021b). Taken together, our results demonstrate that alarmins act by inducing inflammatory responses in the human chorioamniotic membranes, a process that involves the NLRP3 inflammasome.
Once the inflammasome is activated, the ASC adaptor protein assembles into a large intracellular complex known as a “speck” (Fernandes-Alnemri et al, 2007, Vajjhala et al, 2012). Such ASC specks can function as alarmins upon their release into the extracellular space (Balci-Peynircioglu et al, 2008, Baroja-Mazo et al, 2014, Franklin et al, 2014), and thus their detection can serve as an indicator of in vivo inflammasome activation (Stutz et al, 2013). Notably, ASC concentrations were increased in amniotic fluid of women with labor at term (Panaitescu et al, 2019), and were higher in women with clinical chorioamnionitis at term and either sterile or microbial-associated intra-amniotic inflammation (Gomez-Lopez et al, 2019e). Importantly, amniotic fluid ASC concentrations were also increased in patients undergoing preterm labor with either sterile intra-amniotic inflammation or intra-amniotic infection (Gomez-Lopez et al, 2018b), providing additional confirmation that both alarmins and microbes can induce inflammasome activation in the amniotic cavity.
The final step of inflammasome activation is pyroptosis, a type of programmed cell death characterized by the release of cytosolic contents through pores formed in the cell membrane by gasdermin D (GSDMD) (Gaidt and Hornung, 2016, Sborgi et al, 2016, Aglietti and Dueber, 2017, Shi et al, 2017), a protein that is cleaved by active caspase-1 and caspase-11 (Kayagaki et al, 2015, Shi et al, 2015). Amniotic fluid concentrations of GSDMD have been utilized as a readout of in vivo pyroptosis in the amniotic cavity of women who underwent spontaneous term labor and those with spontaneous preterm labor with intact membranes (Gomez-Lopez et al, 2019f, Gomez-Lopez et al, 2021b). Specifically, GSDMD was detectable in the amniotic fluid and chorioamniotic membranes of women with preterm labor and sterile intra-amniotic inflammation or intra-amniotic infection; moreover, the presence of GSDMD was associated with elevated protein expression of caspase-1 and IL-1β in the chorioamniotic membranes (Gomez-Lopez et al, 2019f). These results provide evidence that women with sterile intra-amniotic inflammation undergo inflammasome-mediated pyroptosis in the intra-amniotic space.
A central question that arose from the abovementioned studies is: what is the origin of the alarmins in the amniotic cavity? Alarmins can be released during cellular senescence (Huang et al, 2015) and as a result of tissue injury or non-programmed cellular death (Oppenheim and Yang, 2005, Lotze et al, 2007, Bianchi, 2007, Rider et al, 2017). Notably, cellular senescence of the chorioamniotic membranes has been considered a physiological mechanism of parturition at term (Behnia et al, 2015, Polettini et al, 2015, Bonney et al, 2016, Velarde and Menon, 2016), and in particular, decidual senescence has been proposed as an independent mechanism involved in non-infection-related spontaneous preterm labor (Hirota et al, 2010, Hirota et al, 2011, Romero et al, 2014a, Deng et al, 2016, Cha and Aronoff, 2017). Hence, we evaluated whether the chorioamniotic membranes from women undergoing preterm labor without acute histologic chorioamnionitis exhibit cellular senescence (Gomez-Lopez et al, 2017d). Such tissues presented signs of cellular senescence (Gomez-Lopez et al, 2017d), and thus represent a potential source of alarmins in the amniotic cavity of women with sterile intra-amniotic inflammation who underwent preterm labor and birth.
The studies described herein provide evidence for a role of alarmins and the NLRP3 inflammasome in the chorioamniotic membranes in sterile intra-amniotic inflammation. However, whether the intra-amniotic inflammatory response driven by alarmins is distinct from that initiated by invading microbes is a subject of ongoing investigation. We sought to characterize the transcriptomic differences between the chorioamniotic membranes from women who underwent spontaneous preterm labor with intact membranes and sterile intra-amniotic inflammation and those with intra-amniotic infection by utilizing RNA sequencing (Motomura et al, 2021a). Significant transcriptomic differences were found in the chorioamniotic membranes from women with sterile intra-amniotic inflammation compared to the other study groups, and the immune response in this tissue was milder than that induced by microbes. Importantly, such a response included the upregulation of transcripts for the alarmin S100A8 as well as the inflammasome-related molecules PYCARD, AIM2, and NLRC4 (Motomura et al, 2021a). Furthermore, the chorioamniotic membrane transcriptomes from women with intra-amniotic infection clustered separately from those of women with sterile intra-amniotic inflammation or without inflammation, thus further confirming the distinct nature of the immune response taking place during sterile intra-amniotic inflammation (Motomura et al, 2021a).
Collectively, the abovementioned investigations implicate sterile intra-amniotic inflammation as a new clinical entity that can lead to adverse perinatal outcomes. Such a distinct inflammatory response is triggered by alarmins and involves the activation of the NLRP3 inflammasome in the amniotic cavity.
In general, the treatment of sterile inflammatory processes includes the use of anti-inflammatory medications such as non-steroidal anti-inflammatory (Fullerton, 2013) or corticosteroid (Dougherty and Schneebeli, 1955, Coutinho and Chapman, 2011, Busillo and Cidlowski, 2013) drugs. Other treatments that specifically decrease the concentration of alarmins driving sterile inflammation have also been utilized to treat gout (Terkeltaub, 2003, Pacher et al, 2006, Khanna et al, 2012). However, the majority of these drugs utilized to treat sterile inflammation-related pathologies are not approved for use during pregnancy. Therefore, to date there is no approved treatment for sterile intra-amniotic inflammation. Given the abovementioned role of the NLRP3 inflammasome in sterile intra-amniotic inflammation, we have proposed that the inhibition of NLRP3 inflammasome activation could be used to improve perinatal outcomes. MCC950 is a specific inhibitor of the NLRP3 inflammasome that has been utilized in multiple animal models of diseases such as colitis (Perera et al, 2018), traumatic brain injury (Ismael et al, 2018a, Xu et al, 2018a), and stroke (Ismael et al, 2018b), among others (van der Heijden et al, 2017, Zhai et al, 2018). Therefore, we induced sterile intra-amniotic inflammation in mice via the ultrasound-guided intra-amniotic injection of S100B and showed that treatment with MCC950 drastically reduced preterm birth and neonatal mortality (Gomez-Lopez et al, 2019c). As further proof of this mechanism, we induced sterile intra-amniotic inflammation in Nlrp3−/− mice using IL-1α or S100B and showed that preterm birth and neonatal mortality were similarly reduced ((Motomura et al, 2020a) and Gomez-Lopez et al, unpublished data). However, MCC950 is not approved for use during pregnancy and requires additional research to assess its safety in this regard. Given that IL-1β is a product of inflammasome activation, animal models of intra-amniotic or intra-uterine injection of IL-1β have been utilized to test treatments for intra-amniotic inflammation-associated preterm birth (Sadowsky et al, 2000, Sadowsky et al, 2003, Yoshimura and Hirsch, 2005). Pre-treatment with indomethacin, a tocolytic agent that can be used to delay preterm labor, reduced uterine contractions in catheterized macaques intra-amniotically injected with IL-1β (Sadowsky et al, 2000). Yet, in humans, indomethacin is only recommended for use until 32 weeks of gestation, given the increased risk of closure of the ductus arteriosus in fetuses exposed to it, which limits its potential utility for preventing preterm birth (Vermillion et al, 1997, Macones et al, 2001, American College of Obstetricians and Gynecologists, 2016). Similarly, pre-treatment with either dexamethasone or IL-10 reduced the uterine contractility and the intra-amniotic inflammation induced by the intra-amniotic administration of IL-1β in macaques (Sadowsky et al, 2003). Moreover, pre-treatment with a non-competitive IL-1 receptor ligand, Rytvela, prevented intra-uterine IL-1β-induced preterm birth in mice (Nadeau-Vallee et al, 2017a). Yet, further studies are required to address the safety and usefulness of this promising tool during human pregnancy. Furthermore, to date there are no predictive tools for determining women at risk of sterile intra-amniotic inflammation, and thus pre-treatments are difficult to translate into a clinical setting. Therefore, we explored approaches currently approved for use during pregnancy that could be used to treat sterile intra-amniotic inflammation.
The drug development process can take several years from the discovery to their approval (Kaitin, 2010, Hughes et al, 2011). This process is even more complex during pregnancy due to the physiological changes of pregnant women and the imminent risk of fetal damage (Sheffield et al, 2014, Chappell and David, 2016, Ren et al, 2021). Therefore, the repurposing of drugs that are already approved to be utilized during pregnancy is an optimal approach. Under this premise, and given the urgency to find a treatment for sterile intra-amniotic inflammation, we have investigated two medications that are widely utilized during pregnancy: betamethasone (Galaz et al, 2021) and clarithromycin (Galaz et al, submitted). Betamethasone is a corticosteroid that has become the standard of care for women at risk of delivering preterm, as it has been shown to accelerate fetal organ maturation (American College of Obstetricians and Gynecologists, 2017, McGoldrick et al, 2020). As a corticosteroid, betamethasone has been demonstrated to reduce inflammatory processes in multiple clinical settings (Corbett et al, 1993, Corbel et al, 1999, Matsuo et al, 2009, Ly and Amici, 2018, Zhao et al, 2021). Thus, we recently utilized our model of HMGB1-induced sterile intra-amniotic inflammation to demonstrate that treatment with betamethasone prevented preterm birth; yet, it did not reduce neonatal mortality (Galaz et al, 2021). Ongoing research is investigating the mechanisms whereby betamethasone can extend gestational length. On the other hand, clarithromycin is a macrolide that, together with other antibiotics, has emerged as an effective treatment to be used in the context of intra-amniotic infection/inflammation in women with preterm labor with intact membranes (Yoon et al, 2019), PPROM (Lee et al, 2016a, Lee et al, 2016b), and cervical insufficiency (Oh et al, 2019b, Yeo et al, 2021). Clarithromycin exhibits potent anti-inflammatory properties by acting through the NF-κB and AP-1 pathways (Kikuchi et al, 2002, Yamamoto et al, 2017). Moreover, clarithromycin is the macrolide that most efficiently crosses the placenta (Witt et al, 2003). Importantly, a recent study showed that clarithromycin reduced the amniotic fluid concentrations of IL-6 in women with PPROM and sterile intra-amniotic inflammation (Kacerovsky et al, 2020). Therefore, we undertook a series of animal experiments to investigate whether clarithromycin can be utilized to prevent preterm birth and adverse neonatal outcomes in a model of alarmin-induced sterile intra-amniotic inflammation as well as the underlying mechanisms of action (Galaz et al, submitted). We demonstrated that treatment with clarithromycin prevented HMGB1-induced preterm birth by interfering with the common pathway of parturition as evidenced by dysregulated expression of contractility-associated proteins and inflammatory mediators in the intra-uterine tissues. Notably, clarithromycin improved neonatal mortality by dampening inflammation in the placenta as well as in the fetal lung, intestine, liver, and spleen (Galaz et al, submitted). However, HMGB1-induced neonatal mortality was not fully rescued by clarithromycin treatment. It is worth mentioning that women at risk of preterm birth due to intra-amniotic inflammation/infection are treated with both corticosteroids and antibiotics simultaneously (Lee et al, 2016b, Oh et al, 2019b, Yoon et al, 2019, American College of Obstetricians and Gynecologists, 2020). Hence, further research is required to address whether the combination of betamethasone and clarithromycin, or different drugs that could have synergistic effects, can be used to treat the adverse pregnancy and neonatal outcomes caused by sterile intra-amniotic inflammation.
A unique type of intra-amniotic inflammation driven by fetal T-cell activation: a novel mechanism for preterm labor and birth
The clinical definition of intra-amniotic inflammation considers only the elevated amniotic concentrations of established biomarkers such as IL-6 or MMP-8 (Park et al, 2001, Yoon et al, 2001). Yet, inflammation as a general concept comprises systemic or tissue-wide reaction involving a diverse array of cellular and soluble immune mediators at sites of infection or injury (Abbas et al, 2016). In line with this concept, it has been demonstrated that the intra-amniotic inflammatory response involves the active participation of both maternal and fetal immune cells. Indeed, a pioneer study showed that fetal innate immune cells in the human umbilical cord blood are activated in cases of preterm labor leading to preterm birth compared to term deliveries (Berry et al, 1995). Notably, in this study the cord blood was obtained prior to birth (via cordocentesis), and only a fraction of the preterm neonates were exposed to microbes, thereby suggesting that the fetus itself is able to respond or cause the process of labor (Berry et al, 1995). More recently, we showed that the cord blood of preterm neonates has a population of central memory Th1 cells that is absent in term neonates (Frascoli et al, 2018). Such T cells specifically responded to maternal alloantigens and induced myometrial contractility in vitro (Frascoli et al, 2018). Last, the adoptive transfer of activated T cells into the fetal mice induced pregnancy loss, providing in vivo evidence of a role for activated T cells in adverse pregnancy outcomes (Frascoli et al, 2018). Hence, these studies provided insight into the functions of the fetal adaptive immune system and suggested that the fetus could trigger preterm labor. To confirm these findings, we utilized amniotic fluid samples, which allow the study of the in utero fetal immune response (Gomez-Lopez et al, 2018c). Specifically, we have previously demonstrated the presence of multiple immune cell populations in the amniotic fluid that vary throughout gestation in the absence of intra-amniotic inflammation (Gomez-Lopez et al, 2018c). A prior study also noted that fetal innate lymphoid cells (ILCs) are present in amniotic fluid of women in the absence of intra-amniotic inflammation/infection and that such cells expressed a phenotype indicative of intra-epithelial localization (Marquardt et al, 2016), suggesting that they are derived from fetal tissues and can respond to intra-amniotic inflammation. In light of the above evidence, we evaluated amniotic fluid samples and showed that T cells represent a major subset of leukocytes in preterm pregnancies and that such cells were of fetal origin, as indicated by DNA fingerprinting (Gomez-Lopez et al, 2019g). We also found that fetal CD4+ T cells, but none of the other evaluated leukocyte subsets, were increased in amniotic fluid of women with idiopathic preterm labor (i.e., without intra-amniotic inflammation/infection), which represents the largest subset of preterm labor cases (Gomez-Lopez et al, 2019g). Consistent with the abovementioned findings in amniotic fluid ILCs (Marquardt et al, 2016), fetal T cells expressed markers indicative of mucosal residence, confirming that these cells did not originate from the fetal circulation (Gomez-Lopez et al, 2019g). Furthermore, fetal CD4+ T cells from amniotic fluid samples express cytokines typical of T-cell activation (IL-2, IL-4, and IL-13), suggesting a mild and distinct immune response in idiopathic preterm labor. Moreover, in vitro experiments showed that umbilical cord blood T cells from neonates born to mothers who underwent idiopathic preterm labor and birth displayed enhanced responsiveness compared to those from neonates delivered at term (Gomez-Lopez et al, 2019g), providing novel evidence that fetal T-cell activation is associated with idiopathic preterm labor and birth (Gomez-Lopez et al, 2019g). Last, the ultrasound-guided intra-amniotic injection of activated neonatal CD4+ T cells in pregnant mice resulted in preterm delivery, demonstrating that activated fetal T cells are capable of triggering preterm parturition and, therefore, represent a new mechanism of disease for idiopathic preterm birth (Gomez-Lopez et al, 2019g) (Fig. 1C). Yet, further studies are warranted to understand the mechanisms responsible for the premature activation of fetal T cells in the amniotic cavity.
Given their participation in normal parturition at term, effector T cells have also been implicated in the premature onset of labor. The invasion of cytotoxic T cells into the decidual tissues, termed chronic histological chorioamnionitis, is frequently observed in pregnancies with complications such as spontaneous preterm birth (Kim et al, 2015). More recently, we showed that effector and activated T cells expressing perforin and granzyme B are enriched at the maternal-fetal interface of women who underwent spontaneous preterm labor and birth (Arenas-Hernandez et al, 2019) (Fig. 2A). Consistent with such human findings, the administration of an anti-CD3 antibody to pregnant mice induced the systemic activation of T cells, resulting in preterm birth (Gomez-Lopez et al, 2016b, Arenas-Hernandez et al, 2019) through inflammatory mechanisms that are distinct from those observed in other well-known preterm birth models (Fidel et al, 1994, Dudley et al, 1996, Nadeem et al, 2016, Gomez-Lopez et al, 2018a, Arenas-Hernandez et al, 2019). Furthermore, we recently demonstrated that a subset of decidual T cells co-express IL-22 and RORγt, and that such cells are enriched in women who underwent preterm labor and birth (Gershater et al, 2022, Accepted). The expression of these two molecules, together with the absence of IL-17A, allowed us to propose that such decidual T cells belong to the Th22 subset (Duhen et al, 2009, Liu et al, 2009, Nograles et al, 2009, Trifari et al, 2009). Our finding that Th22-like cells are present at the maternal-fetal interface of women with preterm labor is in line with a previous study showing that decidual IL-22-expressing T cells are implicated in pregnancy loss (Logiodice et al, 2019). Hence, T cells expressing IL-22 are present at the maternal-fetal interface in early and late pregnancy, where they seem to participate in the mechanisms involved in obstetrical disease.
(A) Regulatory T cells serve to suppress effector T cells, thereby preventing a maternal anti-fetal immune response. When the balance between regulatory and effector T cells is disrupted, the activation and infiltration of effector T cells at the maternal-fetal interface can occur, leading to preterm labor and birth. (B) Homeostatic macrophages are important sentinels of the maternal-fetal interface that act as non-antigen specific mediators of maternal-fetal homeostasis and promote fetal development. The inadequate function of these cells can permit the acquisition of a pro-inflammatory phenotype by decidual macrophages as a consequence of preterm labor, emphasizing the importance of homeostatic macrophages in late pregnancy. Importantly, homeostatic macrophages may represent a therapeutic approach to prevent preterm labor and birth.
IL-17-producing T cells (Th17 cells) are a subset of conventionally pro-inflammatory effector T cells that participate in host defense at mucosal/barrier surfaces (Stockinger and Omenetti, 2017). Such cells have been reported as residing at the maternal-fetal interface in early pregnancy (Wu et al, 2014, Lombardelli et al, 2016), and a disruption of the balance between Th17 cells and Tregs is implicated in early pregnancy complications (i.e., spontaneous abortion) (Wang et al, 2010, Nakashima et al, 2010, Lee et al, 2011, Lee et al, 2012, Wu et al, 2016, Zhu et al, 2017). In late pregnancy, studies have suggested that Th17 cells also contribute to the pathophysiology of preeclampsia (Santner-Nanan et al, 2009, Saito, 2010, Fu et al, 2014, Zhang et al, 2018). Notably, such cells are more prevalent in the chorioamniotic membranes from cases of preterm birth with acute chorioamnionitis than in cases without, suggesting that Th17 cells are associated with inflammatory processes at the maternal-fetal interface of women with preterm labor and birth (Ito et al, 2010, Fedorka et al, 2021). In addition to Th17 cells, we have proposed that, under specific conditions, IL-22 is expressed by maternal T cells in the uterine decidua of women with preterm labor and birth (Gershater et al, 2022, Accepted). Under pathological circumstances associated with maternal T-cell activation, IL-22 can cross the maternal-fetal interface and reach the amniotic cavity where it is sensed by the fetal and gestational tissues, causing fetal injury that can lead to neonatal death (Gershater et al, 2022, Accepted).
Alterations in systemic or local Tregs (Sasaki et al, 2007, Prins et al, 2009, Quinn et al, 2011, Nguyen et al, 2017, Tsuda et al, 2018) as well as the Th17/Treg balance (Santner-Nanan et al, 2009, Ding et al, 2019) have been implicated in the pathogenesis of preeclampsia, emphasizing the importance of this adaptive immune subset throughout pregnancy. Yet, little was known of a direct contribution of these cells to spontaneous preterm labor and birth. Accordingly, we recently reported that a subset of women with idiopathic preterm labor and birth displayed a reduction in functional Tregs at the maternal-fetal interface (Gomez-Lopez et al, 2020). This finding correlates with clinical reports showing that women who underwent preterm labor and birth have reduced numbers and function of Tregs in the maternal circulation (Xiong et al, 2010, Schober et al, 2012). Consequently, we utilized a murine model of maternal Treg depletion to demonstrate that the systemic deficiency of Tregs can lead to preterm birth in first and repeat pregnancies; moreover, the loss of such cells induces adverse neonatal outcomes (Gomez-Lopez et al, 2020). The mechanisms whereby the loss of Tregs induces adverse perinatal outcomes involved alterations in the cellular and soluble immune responses in the mother and at the maternal-fetal interface as well as dysregulation of developmental and cellular processes in the placenta (Gomez-Lopez et al, 2020). As a secondary effect, the loss of Tregs also increased maternal susceptibility to preterm birth induced by the administration of LPS (Gomez-Lopez et al, 2020). Importantly, the observed adverse perinatal outcomes were rescued by the adoptive transfer of polyclonal expanded Tregs (Gomez-Lopez et al, 2020). Therefore, we suggested that Tregs play a central role during late pregnancy by modulating systemic and local cellular responses, and that alterations in the proportions or functionality of such cells can promote a pro-inflammatory environment resulting in the development of obstetrical complications such as spontaneous preterm labor in addition to increased susceptibility to infection-induced preterm birth (Fig. 2A).
The evidence presented above underscores the importance of the balance between Treg immunosuppressive functions throughout pregnancy and the controlled activity of effector T cells for successful maternal-fetal tolerance. Thus, pregnancy interventions that promote such a balance, whether directly or as a secondary effect, are of great interest. We have shown that two commonly utilized treatments, vaginal progesterone and human chorionic gonadotropin (hCG), both display immunomodulatory effects that include an increased proportion of Tregs in the decidual tissues in mice (Furcron et al, 2015, Furcron et al, 2016). Such an effect is likely mediated through the glucocorticoid receptor (GR) by which progesterone can induce conventional T-cell apoptosis, thereby resulting in an increased proportion of Tregs (Engler et al, 2017). We have also shown that progesterone exerts complementary reduction of inflammatory responses at the maternal-fetal interface in a model of systemic maternal T-cell activation-induced preterm birth (Arenas-Hernandez et al, 2019), and thus such a treatment can address both components of effector T cell/Treg imbalance associated with preterm birth.
A number of different cellular and molecular approaches directed at conventional T cells or Tregs have been utilized to treat conditions such as autoimmune disease or graft-versus-host disease (GVHD) (Esensten et al, 2018, Ferreira et al, 2019). While successful in some cases, the potential application of such treatments during pregnancy highlights some challenges. With regard to cellular approaches, multiple clinical trials have shown benefits of administering ex vivo expanded polyclonal Tregs to patients with various diseases (Esensten et al, 2018); yet, animal studies have indicated that infusion of antigen-specific Tregs may be more potent in conditions such as diabetes (Green et al, 2002, Tang et al, 2004, Esensten et al, 2018). In one of these studies, it was demonstrated that adoptively transferring Tregs derived from the pancreatic lymph nodes to recipient mice prevented diabetes development (Green et al, 2002); however, such a strategy would be largely non-applicable in humans, particularly during pregnancy, as obtaining Tregs from lymphoid organs adjacent to the target tissue is not feasible. Nonetheless, we have shown that the adoptive transfer of polyclonal Tregs in mice could successfully prevent the impending adverse pregnancy outcomes induced by a reduction of these cells (Gomez-Lopez et al, 2020). For the majority of diseases, the use of engineered T-cell receptors (TCRs) or chimeric antigen receptor (CAR) Tregs can be applied at least in theory, given that candidate antigens have typically been identified (Ferreira et al, 2019). On the other hand, while it is presumed that paternal/fetal antigens are those driving maternal anti-fetal rejection, the identification of epitopes that could be used to engineer specific Tregs is difficult and remains a major limitation of immunological investigations during pregnancy.
Aside from cellular therapies, strategies to take advantage of the mediators required for and produced by effector and regulatory T cells have also been explored for treating inflammatory diseases. Interleukin-2 is essential for the development and suppressive functions of Tregs, which constitutively express CD25 [a component of the high-affinity IL-2 receptor (Tang, 2015)]. Thus, it was reasoned that low-dose IL-2 treatment could preferentially boost Tregs without initiating systemic immune activation (Tang, 2015). Prior and ongoing clinical trials have shown some success in alleviating symptoms in patients with GVHD or systemic lupus erythematosus (SLE), among others (Ferreira et al, 2019), and it is possible that a combination of expanded Treg infusion together with low-dose IL-2 could ensure that transferred cells are maintained and even expanded. However, normal pregnancy is characterized by low-grade systemic inflammation and immune activation (Sacks et al, 1998, Naccasha et al, 2001, Kraus et al, 2012) that can be exacerbated in the context of disease, and thus substantial research is required to evaluate whether the administration of IL-2 during pregnancy would be detrimental. The corticosteroid prednisone is clinically used in a variety of immune-related diseases and can promote the function and expansion of Tregs (Fu et al, 2019). Indeed, in vitro prednisone treatment increased the proportion of Tregs among isolated first trimester decidual lymphocytes and inhibited Th17 cells (Fu et al, 2017). Moreover, a clinical trial provided evidence that prednisone increased peripheral Tregs and improved pregnancy success in repeated implantation failure (RIF) patients (Huang et al, 2021). Last, vitamin D exerts well-documented anti-inflammatory effects that include induction of IL-10 and inhibition of Th9 and Th17 cells (Palmer et al, 2011, Korf et al, 2012). Indeed, given its modulation of the Treg/Th17 ratio, insufficient vitamin D has been implicated in pregnancy complications such as preeclampsia (Muyayalo et al, 2019, Ribeiro et al, 2021), preterm labor (Zahran et al, 2018), and recurrent pregnancy loss (Ji et al, 2019), which could be improved by supplementation (Chen et al, 2020). Thus, a number of treatment options exist that could be utilized to boost Treg functions and numbers and potentially improve pregnancy outcomes.
An alternative approach to boosting Tregs could be the targeted inhibition of specific mediators released by effector T-cell subsets. An ongoing line of investigation in our laboratory has indicated that the cytokine IL-22, which is primarily produced by the Th22 subset (in the absence of IL-17A) at the maternal-fetal interface, can cross from the maternal side to the amniotic cavity and be sensed by the binding protein expressed by fetal and gestational tissues, causing tissue damage and leading to adverse short- and long-term neonatal outcomes (Gershater et al, 2022, Accepted). Thus, in the context of specific pregnancy complications, therapeutic approaches directed at diminishing the concentrations or activity of specific T cell-associated mediators could also represent a viable approach.
The evidence provided above demonstrates that Tregs are an essential component of maternal-fetal tolerance. Yet, we have shown using animal models that the impaired presence of Tregs in late pregnancy only accounts for a small proportion of preterm births (Gomez-Lopez et al, 2020). Therefore, we considered that other immune cells besides Tregs must participate in maintaining maternal-fetal homeostasis. Macrophages constitute the second-largest population of leukocytes (20–30%) at the maternal-fetal interface (Lessin et al, 1988, Williams et al, 2009), and contribute to multiple processes required for pregnancy establishment including embryo implantation (Jaiswal et al, 2012, Care et al, 2013, Schumacher et al, 2018), trophoblast invasion (Tan et al, 2014, Ding et al, 2021), and spiral artery remodeling (Hazan et al, 2010, Lash et al, 2016). In addition, a large number of investigations have explored the phenotypes of decidual macrophages and noted that the majority of this subset display unique functions and phenotypes that most closely resemble anti-inflammatory or M2-like macrophages (Hunt et al, 1984, Gustafsson et al, 2008, Nagamatsu and Schust, 2010, Svensson et al, 2011, Houser et al, 2011, Svensson-Arvelund et al, 2015, Svensson-Arvelund and Ernerudh, 2015, Xu et al, 2016, Chambers et al, 2020). Therefore, we recently proposed that macrophages in the uterine decidua exert anti-inflammatory functions during late pregnancy that promote maternal-fetal homeostasis and thereby sustain gestation prior to term labor (Gomez-Lopez et al, 2021a) (Fig. 2B). We applied a model of pregnant Cd11bDTR/DTR mice wherein CD11b+ macrophages could be depleted upon administration of diphtheria toxin (Duffield et al, 2005, Cailhier et al, 2005), which has been shown to impair fetal development (Yellon et al, 2019) and result in pregnancy loss in early gestation (Robertson et al, 2008, Care et al, 2013). Using this approach, we demonstrated that macrophage depletion in late pregnancy resulted in preterm birth in the majority of dams (75%) (Gomez-Lopez et al, 2021a). More importantly, the majority of pups born to macrophage-depleted dams did not survive past the first 24 hours of life, suggesting that the loss of maternal macrophages may have adverse effects beyond intra-uterine life (Gomez-Lopez et al, 2021a). A causal link between maternal macrophage depletion and adverse pregnancy outcomes was mechanistically demonstrated by adoptively transferring bone marrow-derived macrophages (BMDMs) into macrophage-depleted dams, which successfully reduced the preterm birth rate but did not improve neonatal survival (Gomez-Lopez et al, 2021a). We reasoned that, given the homeostatic phenotypes attributed to macrophages at the maternal-fetal interface (Hunt et al, 1984, Gustafsson et al, 2008, Nagamatsu and Schust, 2010, Svensson et al, 2011, Houser et al, 2011, Svensson-Arvelund et al, 2015, Svensson-Arvelund and Ernerudh, 2015, Xu et al, 2016, Chambers et al, 2020), the in vitro polarization of BMDMs prior to their adoptive transfer may improve their effectiveness. We utilized our translationally-relevant model of intra-amniotic inflammation induced by the ultrasound-guided intra-amniotic injection of LPS to demonstrate that the administration of M2-polarized macrophages not only drastically reduced preterm births but decreased neonatal mortality, thereby demonstrating the importance of homeostatic macrophages for pregnancy maintenance as well as neonatal survival (Gomez-Lopez et al, 2021a). Molecular investigation revealed that the adoptive transfer of M2-polarized macrophages reduced inflammation in the maternal circulation and amniotic fluid as well as downregulated inflammatory gene expression in fetal tissues such as the brain and lung (Gomez-Lopez et al, 2021a), providing mechanistic insight into the protective effects of these homeostatic cells for the mother and fetus.
Currently, multiple anti-inflammatory therapies have been tested to prevent preterm labor caused by inflammation (Wakabayashi et al, 2013, Sykes et al, 2014, Xu et al, 2016, Chin et al, 2016, Kadam et al, 2017, Garcia-Flores et al, 2018, Gomez-Lopez et al, 2019c). Given the demonstrated importance of macrophage polarization for pregnancy outcomes, we showed that rosiglitazone can be used to treat LPS-induced preterm birth by activating the PPARγ pathway, thereby reducing decidual macrophage-mediated inflammation (Xu et al, 2016). However, we reasoned that the adoptive transfer of M2-polarized macrophages may represent a more direct approach. The in vitro generation of M2-polarized macrophages have been studied and applied as therapeutic treatments in cancer (Andreesen et al, 1998), diabetes (Parsa et al, 2012), neuropathic pain (Pannell et al, 2016), and other inflammatory diseases (Wang et al, 2007, Weber et al, 2007, Hunter et al, 2010), with minimal adverse effects being reported (Andreesen et al, 1998). Investigations in which the transferred M2 macrophages were tracked suggested that these cells will preferentially target inflamed tissues, such as the pancreas in diabetic mice (Parsa et al, 2012). Moreover, the intrathecal administration of M2 macrophages yielded a significant neurological improvement in human patients undergoing treatment for stroke (Chernykh et al, 2016). Such clinical and animal studies, together with current knowledge of the important role for macrophages throughout gestation, hinted that this strategy could be useful during pregnancy. Accordingly, we recently demonstrated that adoptively transferring macrophages polarized to an M2-like phenotype in vitro prevented preterm birth and, more importantly, improved neonatal outcomes in a model of LPS-induced intra-amniotic inflammation (Gomez-Lopez et al, 2021a). Such outcomes point to the potential viability of M2-polarized macrophages as a treatment option for women at risk for delivering preterm. It is worth mentioning that such a treatment would not be suitable for all cases of spontaneous preterm labor. Indeed, as described above, administering an antibiotic regimen is considered the optimal approach for treating spontaneous preterm labor associated with intra-amniotic infection (Yudin et al, 2009, Lee et al, 2016b, Yoon et al, 2019). Thus, the adoptive transfer of M2-polarized macrophages could represent a treatment option for sterile intra-amniotic inflammation; yet, further research is required to demonstrate the feasibility of such an approach.
Conclusion
In summary, here we have provided an overview of the immune mechanisms implicated in intra-amniotic inflammation, the best-characterized cause of preterm labor and birth. While the inflammatory processes driven by microbes (infection) or alarmins (sterile) have some overlap in their participating cellular and molecular processes, the distinct natures of these two conditions necessitate the implementation of specific approaches to prevent adverse pregnancy and neonatal outcomes (Fig. 1A&B). Intra-amniotic infection can be treated using the right antibiotics, whereas sterile intra-amniotic inflammation could be potentially treated using a combination of anti-inflammatory drugs (e.g., betamethasone, inflammasome inhibitors, etc.). Importantly, we have also described the current evidence supporting fetal T-cell activation as a newly described trigger for preterm labor and birth in a subset of cases (Fig. 1C). These findings represent an exciting area of future research focused on further elucidating the fetal immune mechanisms implicated in such a response. Recently, we also provided evidence of two potential immune mechanisms responsible for a subset of preterm births formerly considered to be idiopathic. In the first, we have shown that the impairment of maternal Tregs leads to preterm birth, likely due to the loss of immunosuppressive activity resulting in unleashed effector T-cell responses (Fig. 2A). Second, we have demonstrated the importance of homeostatic macrophages for maintaining pregnancy and promoting fetal development as well as the effectiveness of the adoptive transfer of M2-polarized macrophages for preventing inflammation-induced preterm birth (Fig. 2B). Collectively, in this review, we have discussed established and novel immune mechanisms responsible for preterm birth and highlighted potential targets for novel strategies aimed at preventing the multi-etiological syndrome of preterm labor.
KEY POINTS
Intra-amniotic inflammation, driven by microbes ascending from the lower genital tract (intra-amniotic infection) or by alarmins (i.e. danger signals) released upon cellular stress or damage (sterile intra-amniotic inflammation), is the best-established causal link to preterm labor and birth. While intra-amniotic infection can be treated using the correct antibiotic regimen, sterile intra-amniotic inflammation currently lacks approved treatment. Yet, ongoing investigations have identified several promising approaches that could be used to treat women with this clinical condition.
Pregnancy involves unique mechanisms of maternal-fetal tolerance. Recent investigations have expanded this concept by showing that fetal T cells respond to maternal antigens and are implicated in premature onset of labor leading to preterm birth.
Maternal-fetal tolerance includes several mechanisms that regulate maternal T cells, including the induction of an exhausted or senescent state, silencing of T-cell chemoattractant expression at the maternal-fetal interface, and the expansion of regulatory T cells (Tregs). A breakdown of such maternal-fetal tolerance, either through the aberrant activation of effector T cells or the impaired functionality of Tregs, can result in preterm labor and birth.
Macrophages represent a critical cellular component of the maternal-fetal interface. Such cells exert anti-inflammatory functions to promote maternal-fetal homeostasis until term, when they acquire a pro-inflammatory phenotype to promote labor. The importance of macrophages was further established by showing that the impairment of these cells during pregnancy results in preterm labor and birth. Importantly, homeostatic macrophages may represent a viable cellular approach to treat sterile intra-amniotic inflammation.
Funding
This research was supported by the Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S Department of Health and Human Services (NICHD/NIH/DHHS) under Contract No HHSN275201300006C. This research was also supported by the Wayne State University Perinatal Initiative in Maternal, Perinatal and Child Health. R.R. has contributed to this work as part of his official duties as an employee of the United States Federal Government. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Equils O, Kellogg C, Mcgregor J, Gravett M, Neal-Perry G Gabay C 2020. The role of the IL-1 system in pregnancy and the use of IL-1 system markers to identify women at risk for pregnancy complicationsdagger. Biol Reprod, 103, 684–694. [PubMed] [Google Scholar]
Myers DA 2012. The recruitment and activation of leukocytes into the immune cervix: further support that cervical remodeling involves an immune and inflammatory mechanism. Biol Reprod, 87, 107. [PubMed] [Google Scholar]
Timmons BC Mahendroo MS 2006. Timing of neutrophil activation and expression of proinflammatory markers do not support a role for neutrophils in cervical ripening in the mouse. Biol Reprod, 74, 236–45. [PubMed] [Google Scholar]
Want to print your doc?
This is not the way.
Try clicking the ⋯ next to your doc name or using a keyboard shortcut (
CtrlP
) instead.